49, Bd du Général Martial Valin
Paris 75015
France
33 1 45 58 76 00
https://valeriotx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 39
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Shefali Agarwal M.D., MPH | President, CEO & Chairwoman | N/A | N/A | 1973 |
Ms. Joyce Carey | Executive Director of Finance and Head of FP&A | N/A | N/A | N/A |
Ms. Robin Sutherland | VP & Global Head of Human Resources | N/A | N/A | N/A |
Mr. Michel Forest | Chief Pharmacist & Quality Assurance Director | N/A | N/A | N/A |
Ms. Huiping Jiang | Senior Vice President of Regulatory Affairs & Quality Assurance | N/A | N/A | N/A |
Mr. Wael Jdey Ph.D. | Head of Preclinical | N/A | N/A | N/A |
Dr. Donna Cabral-Lilly Ph.D. | VP & Head of CMC | N/A | N/A | N/A |
Ms. Pam Slatcher | Head of Global PV | N/A | N/A | N/A |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Valerio Therapeutics Société anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.